申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0194746A2
公开(公告)日:1986-09-17
The invention provides a compound of formula (1):-
and pharmaceutically acceptable salts thereof, where
R' and R2 are the same or different and are hydrogen, C1-6 alkyl, C1-6 alkoxy or halogen;
R3 is optionally substituted phenyl or optionally substituted pyridyl, where the optional substituents are one or more C1-6 alkyl, C1-6 alkoxy, or hydroxy groups or halogen atoms; or furanyl or thienyl optionally substituted by a C1-6 alkyl group;
a is from 1 to 6;
b is from 2 to 4;
R4 is CH2R5 where R5 is phenyl substituted by sulphonamido or a carboxyl group or an ester thereof, pyridyl substituted with a carboxyl group or an ester thereof and optionally further substituted with a C1-6 alkyl group, N-oxo-pyridyl optionally substituted with a C1-6 alkyl group, or an imidazolyl, pyridazinyl, pyrimidinyl, pyrazinyl or benzimidazolyl group; and
r is 1 or 2.
The compounds are useful as histamine H1-antagonists.
本发明提供了式(1)化合物
及其药学上可接受的盐类,其中
R' 和 R2 相同或不同,并且是氢、C1-6 烷基、C1-6 烷氧基或卤素;
R3 是任选取代的苯基或任选取代的吡啶基,其中任选取代基是一个或多个 C1-6 烷基、C1-6 烷氧基或羟基或卤原子;或任选被 C1-6 烷基取代的呋喃基或噻吩基;
a 是 1 至 6
b 是 2 至 4;
R4 是 CH2R5,其中 R5 是被磺酰胺基或羧基或其酯取代的苯基,被羧基或其酯取代并可选地被 C1-6 烷基进一步取代的吡啶基,可选地被 C1-6 烷基取代的 N-氧代吡啶基,或咪唑基、哒嗪基、嘧啶基、吡嗪基或苯并咪唑基;以及
r 为 1 或 2。
这些化合物可用作组胺 H1 拮抗剂。